Retatrutide Dosage Protocol (50 mg Vial)

Straightforward 12-week and 24-week planning for a 50 mg vial at 20 mg/mL.

• Retatrutide vials (50 mg each):
  • Phase 2, 12 weeks: Minimum 2 vials (56 mg required).
  • Phase 2, 24 weeks: Minimum 4 vials (200 mg required).
  • Phase 3, 12 weeks: Minimum 1 vial (48 mg required).
  • Phase 3, 24 weeks: Minimum 4 vials (180 mg required).
• U-100 insulin syringes (1 mL capacity):
  • Phase 2, 12 weeks: 12 new syringes.
  • Phase 2, 24 weeks: 24 new syringes.
  • Phase 3, 12 weeks: 12 new syringes.
  • Phase 3, 24 weeks: 24 new syringes.
• Bacteriostatic water (10 mL bottles):
  • Phase 2, 12 weeks: 1 bottle by volume (5 mL required).
  • Phase 2, 24 weeks: 1 bottle by volume (10 mL required).
  • Phase 3, 12 weeks: 1 bottle by volume (2.5 mL required).
  • Phase 3, 24 weeks: 1 bottle by volume (10 mL required).
• Alcohol swabs:
  • Phase 2, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 2, 24 weeks: 48 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 24 weeks: 48 swabs minimum; 1 box of 100 covers the calculation.

Sharps disposal: One appropriately sized container for used syringes.

Stability planning: Vial and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.

Retatrutide 50 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 2.5 mL of bacteriostatic water to produce 20 mg/mL.
• U-100 conversion: At 20 mg/mL, 1 unit = 0.01 mL = 200 mcg.
• Trial schedule: Published programs evaluated once-weekly subcutaneous dosing with staged escalation.^[1][2][3][5]
• Chart amounts: The tables translate 2, 4, 6, 8, 9, and 12 mg into volume markings without creating a recommendation.
• 50 mg vial yield: One vial contains 25 calculations at 2 mg, 12.5 at 4 mg, 6.25 at 8 mg, or about 4.17 at 12 mg before preparation limits are considered.
• Evidence boundary: Retatrutide remains investigational. These calculations organize published research schedules and do not establish individualized dosing, safety, or suitability.^[1][3][5][6]

Key facts for interpreting the 50 mg calculation page.

• Compound: Retatrutide, an investigational GIP, GLP-1, and glucagon receptor agonist.^[4][7][8]
• Route and frequency in trials: Subcutaneous injection once weekly.^[1][3][5][6]
• Prepared concentration: 50 mg ÷ 2.5 mL = 20 mg/mL.
• U-100 conversion: 1 unit = 0.01 mL = 0.2 mg (200 mcg).
• Studied targets: Published programs included 4 mg, 8 mg, 9 mg, and 12 mg targets after protocol-defined starting doses and escalation.^[1][2][3][5]

How to distinguish amount, escalation, and vial-strength math.

• Amount per administration: Each chart row is one once-weekly amount, not a daily total.^[1][3][5]
• Starting dose: Some trial arms began at 2 mg before increasing to higher assigned targets.^{[1][2][3][5][10][12]}
• Step-up schedule: Escalation was part of the phase 2 and phase 3 clinical trials and differed by trial; the two tables should not be combined.^{[1][2][3][5][6]}
• Vial strength: A 50 mg vial changes concentration, unit markings, theoretical yield, and supplies - not the evidence-based dose range.
• Research record: Track the assigned protocol, week, amount, calculated units, mL, lot, date, and injection site.

Preparation records and stability limits remain product specific.

• Label the vial: Record compound, 20 mg/mL concentration, preparation date, and lot or source identifier.
• Follow verified instructions: Storage temperature, light protection, and discard timing must come from the exact product or study documentation.
• Do not infer a universal use-by period: Vial strength alone does not establish post-reconstitution stability.
• Limit temperature cycling: Protein and peptide stability can be affected by repeated freeze-thaw exposure.^[16]
• Maintain sterile technique: Use a new sterile syringe and appropriate sharps disposal practices.^[13][14][15]

The 50 mg strength changes the arithmetic, not the trial amount. These examples show how the 20 mg/mL concentration maps to a U-100 syringe.

• 2 mg: 0.10 mL = 10 units; a 50 mg vial contains 25 theoretical 2 mg portions.
• 4 mg: 0.20 mL = 20 units; a 50 mg vial contains 12.5 theoretical 4 mg portions.
• 6 mg: 0.30 mL = 30 units; a 50 mg vial contains about 8.33 theoretical 6 mg portions.
• 8 mg: 0.40 mL = 40 units; a 50 mg vial contains 6.25 theoretical 8 mg portions.
• 9 mg: 0.45 mL = 45 units; a 50 mg vial contains about 5.56 theoretical 9 mg portions.
• 12 mg: 0.60 mL = 60 units; a 50 mg vial contains about 4.17 theoretical 12 mg portions.
• Theoretical yield does not account for dead space, handling loss, sterility limits, or the product-specific discard date.

Retatrutide dosage research used assigned study arms rather than one universal schedule. The evidence must be read by population, target dose, starting dose, and escalation design.

• The phase 2 obesity trial evaluated once-weekly 1 mg, 4 mg, 8 mg, and 12 mg groups; several higher-target arms began at 2 mg or 4 mg and escalated.^[1][6][10]
• The retatrutide dose in each clinical trial followed a preset dosing schedule. In the phase 2 trial, some participants started at 2 mg once weekly before dose increases every 4 weeks toward an assigned 4 mg, 8 mg, or 12 mg target; the published trials were sponsored by Eli Lilly.^{[1][5][10][12]}
• The phase 2 type 2 diabetes trial evaluated 0.5 mg, 4 mg, 8 mg, and 12 mg retatrutide groups, with multiple escalation designs.^[5][12]
• The TRIUMPH phase 3 program specified target doses and escalation schedules for obesity-related research.^[2]
• TRANSCEND-T2D-1 evaluated 4 mg, 9 mg, and 12 mg target doses in adults with type 2 diabetes inadequately controlled with diet and exercise.^[3]
• A starting dose, step-up schedule, and highest studied target are trial variables; they should not be restated as individualized instructions.

Retatrutide was engineered as a single peptide with agonist activity at three metabolic hormone receptors.

• The molecule activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.^[4]
• The triple agonist design is being studied for integrated effects on appetite, glucose regulation, energy balance, and body weight.^[4][7][8]
• Multi-receptor activity does not make results interchangeable with semaglutide, tirzepatide, or other incretin-based compounds; each evidence base and trial schedule must be evaluated separately.^[7][8][9]
• Retatrutide remains investigational, and ongoing research continues to define efficacy, safety, and appropriate study populations.^[2][3][6]

Results should be tied to the population and endpoint studied rather than generalized from the vial size.

• In adults with obesity, the phase 2 trial reported dose-dependent body-weight changes through 48 weeks across once-weekly study arms.^[1]
• In adults with type 2 diabetes, the phase 2 trial examined glycated hemoglobin and body-weight outcomes through 24 and 36 weeks.^[5]
• The phase 3 TRANSCEND-T2D-1 trial evaluated 4 mg, 9 mg, and 12 mg targets and reported glycemic and body-weight outcomes in its enrolled population.^[3]
• A phase 2a substudy in participants with metabolic dysfunction-associated steatotic liver disease evaluated changes in liver fat at 24 weeks.^[11]
• These findings do not validate a 50 mg vial, a compounded product, or any unsupervised protocol; the vial calculation is separate from clinical evidence.

Safety interpretation depends on the studied population, starting dose, escalation rate, target dose, and duration.

• Retatrutide side effects: Gastrointestinal events - including nausea, diarrhea, vomiting, and constipation - were commonly reported in phase 2 research and varied across dose and escalation groups.^{[1][5][10][12]}
• In the obesity phase 2 trial, dose-dependent heart-rate increases peaked during the study and later declined.^[1]
• Trial protocols used eligibility criteria, clinical monitoring, and prespecified escalation; a vial-math page cannot reproduce those safeguards.^[1][3][5][6]
• The evidence does not establish a general maintenance dose or maximum dose for an individual outside a research protocol.
• Preparation quality and repeated temperature changes can also affect peptide stability, so use product-specific storage instructions.^[16]

A clear log helps separate concentration math from the assigned protocol and supports reproducible research records.

• Record the vial strength, diluent volume, calculated concentration, lot, preparation date, and verified storage conditions.
• For each administration, record the protocol week, assigned amount, calculated mL, U-100 units, date, and injection site.
• Rotate subcutaneous sites and use clean equipment according to the governing study procedure.^[13][14][15]
• Document deviations, missed observations, adverse events, and changes directed by the study investigator rather than improvising a catch-up schedule.
• Keep supplier pages and product labels separate from scientific evidence; use the cited literature to interpret trial claims.

Common calculation questions about this vial strength can be answered without turning research arithmetic into medical advice.

• What concentration results from adding 2.5 mL? A 50 mg vial divided by 2.5 mL produces 20 mg/mL.
• How many mcg are in one U-100 unit? One unit is 0.01 mL, so at 20 mg/mL it contains 0.2 mg, or 200 mcg.
• Does a 50 mg vial change the retatrutide dosage schedule? No. Vial strength changes the volume calculation and theoretical yield, while the cited trials define their own assigned amounts and escalation.^[1][2][3][5]
• What was the highest studied weekly target in the cited programs? The cited phase 2 and phase 3 sources include 12 mg once weekly as a target, but that is a trial parameter - not a recommendation.^{[1][2][3][5][6]}
• Was a gradual dose escalation used? Yes. In several phase 2 trial arms, participants started at 2 mg once weekly before dose increases every 4 weeks according to the assigned study protocol.^{[1][5][10][12]}
• Is retatrutide approved for routine use? No. Retatrutide remains investigational; this page is an educational calculation reference for published research.^[2][3][6]

Important: This page is for educational and research use only. Retatrutide remains investigational, and the 50 mg vial calculations do not establish an individualized starting dose, escalation schedule, maintenance dose, or maximum dose.^[2][3][6]

• 1
  New England Journal of Medicine (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity: randomized phase 2 trial

  View Source
• 2
  Diabetes, Obesity and Metabolism (2026): TRIUMPH Phase 3 trial design, target doses, and escalation

  View Source
• 3
  The Lancet (2026): TRANSCEND-T2D-1 randomized phase 3 retatrutide trial

  View Source
• 4
  Cell Metabolism (2022): Discovery and translational pharmacology of LY3437943

  View Source
• 5
  The Lancet (2023): Retatrutide for type 2 diabetes: randomized phase 2 trial

  View Source
• 6
  ClinicalTrials.gov: Phase 2 retatrutide obesity study NCT04881760

  View Source
• 7
  Current Obesity Reports (2025): Triple agonism-based therapies for obesity

  View Source
• 8
  Nature Reviews Endocrinology (2024): Multi-receptor agonists for metabolic disease

  View Source
• 9
  Diabetes Care (2024): Incretin-based therapies and cardiovascular considerations

  View Source
• 10
  New England Journal of Medicine (2023): Supplementary material for the phase 2 obesity trial

  View Source
• 11
  Nature Medicine (2024): Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: randomized phase 2a trial

  View Source
• 12
  The Lancet (2023): Supplementary data for the phase 2 diabetes trial

  View Source
• 13
  CDC: Subcutaneous administration guidance

  View Source
• 14
  Johns Hopkins Arthritis Center: How to give a subcutaneous injection

  View Source
• 15
  NCBI Bookshelf: Best practices for injections and related procedures

  View Source
• 16
  Journal of Pharmaceutical Sciences (2018): Stability considerations during freeze-thaw cycles

  View Source

Compare the other Retatrutide vial sizes and practical measurement guides.